Molecular Profiling and Precision Medicine: The Revolution Driving the Global Soft Tissue Sarcoma Market Towards Persona
The landscape of soft tissue sarcoma (STS) treatment is undergoing a profound transformation, spearheaded by the advent of comprehensive molecular diagnostics and precision medicine approaches. Soft tissue sarcomas represent a highly heterogeneous group of cancers, with over 50 distinct histological subtypes, each exhibiting unique genetic signatures. The traditional one-size-fits-all approach of conventional chemotherapy is rapidly being replaced by a more nuanced strategy where treatment is tailored to the specific molecular and genetic alterations within a patient’s tumor.
This shift is fundamentally driven by technological leaps in next-generation sequencing (NGS), which have made routine molecular profiling clinically and economically feasible, allowing oncologists to identify actionable mutations and fusion proteins such that treatment can be highly personalized.